Our lead peptide under development is a melanocortin-4 receptor antagonist to treat the lean body wasting condition of cachexia. Cachexia is produced by many chronic diseases, including cancer, heart disease, and renal failure. In addition, the presence of cachexia (e.g. produced by cancer) can lead to multiple organ failure, due to catabolic effects on organs such as the heart. The global effects of cachexia are mediated by high metabolic rate induced apoptosis; programmed cell suicide....
Our lead peptide under development is a melanocortin-4 receptor antagonist to treat the lean body wasting condition of cachexia. Cachexia is produced by many chronic diseases, including cancer, heart disease, and renal failure. In addition, the presence of cachexia (e.g. produced by cancer) can lead to multiple organ failure, due to catabolic effects on organs such as the heart. The global effects of cachexia are mediated by high metabolic rate induced apoptosis; programmed cell suicide.
More information

Investors

kenneth gruber
Admin
kenneth gruber

Employees

Kenneth Gruber
Admin
Kenneth Gruber CEO Founder and Company President/CEO. I also function as the CSO